{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T06:53:52Z","timestamp":1791010432480,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008751","name":"Bundesinstitut f\u00fcr Risikobewertung","doi-asserted-by":"publisher","award":["60- 0102-01.P640"],"award-info":[{"award-number":["60- 0102-01.P640"]}],"id":[{"id":"10.13039\/501100008751","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008751","name":"Bundesinstitut f\u00fcr Risikobewertung","doi-asserted-by":"publisher","award":["60- 0102-01.P640"],"award-info":[{"award-number":["60- 0102-01.P640"]}],"id":[{"id":"10.13039\/501100008751","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Brigitte and Dr. Konstanze Wegener Stiftung"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glioblastoma (GBM) remains a highly lethal brain tumor with limited therapeutic options and pervasive resistance to standard treatments. Cyclin-dependent kinases (CDKs), key regulators of cell cycle progression and transcription, are frequently dysregulated in GBM and contribute to tumor pathogenesis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We employed a range of preclinical GBM models\u2014including 2D cultures, 3D spheroids, patient-derived organoids (PDOs), and multicellular 3D bioprints\u2014to evaluate the effects of the CDK2\/9 inhibitor fadraciclib in comparison to the standard-of-care temozolomide. Endpoints included cell viability, stress responses, immune-modulatory effects, and transcriptomic reprogramming.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fadraciclib robustly reduces cell viability and invasion in all patient-specific 2D- and 3D models. This effect was independent of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status, demonstrating superior efficacy to temozolomide. Mechanistically, fadraciclib disrupted lysosomal, mitochondrial, and endoplasmic reticulum integrity and increased \u03b3H2AX levels, indicating enhanced DNA double-strand breaks. Seahorse analysis demonstrated impaired mitochondrial bioenergetics following fadraciclib treatment. In a triple-culture blood-brain barrier (BBB) model, fadraciclib demonstrated effective BBB penetration and antitumoral activity against GBM cells, while exhibiting minor cytotoxicity toward brain-specific normal cells. In semi-autologous co-culture systems, fadraciclib inhibited GBM invasion, promoted intercellular communication via Connexin 43 upregulation in microglia, and activated peripheral T cells. Transcriptomic analyses of treated patient-derived organoids revealed widespread transcriptional reprogramming, including downregulation of oncogenic long non-coding RNAs (\n                      <jats:italic>MALAT1<\/jats:italic>\n                      ,\n                      <jats:italic>POM121L9<\/jats:italic>\n                      ), suppression of immune-related pathways, and upregulation of the tumor suppressor\n                      <jats:italic>LZTS1<\/jats:italic>\n                      . Increased histone-associated gene expression suggests chromatin remodeling and induction of a quiescent tumor cell state. Subtype analysis indicated a shift toward a proneural molecular signature. Notably, the antitumoral effects of fadraciclib were preserved in multicellular biomimetic bioprints, whereas nonmalignant astrocytes and microglia were not affected. Therapeutic activity also coincided with altered secretion profiles of extracellular vesicles (EV). EVs from reactive astrocytes contained higher amounts of Fas, which may act as modulator of neuroinflammation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CDK2\/9 inhibition shows promise as a therapeutic strategy for GBM. Fadraciclib exhibits multifaceted anti-tumor activity and spares nonmalignant cells of the central nervous system, supporting its further development in therapies that target transcriptional and immune pathways, as well as quiescent tumor cell populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12964-026-03272-6","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T11:13:41Z","timestamp":1790939621000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CDK2\/9 blockade remodels chromatin and drives phenotypic plasticity in glioblastoma organoids"],"prefix":"10.1186","volume":"24","author":[{"given":"Philipp","family":"Kaps","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Sophie","family":"Hieltscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Auditore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kamper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie-Charlotte","family":"Nelz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Heskamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Mei\u00dfner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabell","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Brandstetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Grabarczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Troschke-Meurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burkhard","family":"Hinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Wittig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Dubinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Gessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Freiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"St\u00e4hlke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp-Kjell","family":"Ficht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Boeckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Polley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl-Friedrich","family":"Classen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Junghanss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Maletzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"key":"3272_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/CAAC.21660","volume":"71","author":"J Hyuna Sung","year":"2021","unstructured":"Hyuna Sung J, Ferlay RL, Siegel M, Laversanne I, Soerjomataram A, Jemal FB. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/CAAC.21660.","journal-title":"Cancer J Clin"},{"key":"3272_CR2","doi-asserted-by":"publisher","unstructured":"Quinn T, Ostrom SS, Francis, Jill S, Barnholtz-Sloan. Epidemiology of Brain and Other CNS Tumors. Curr Neurol Neurosci Rep. 2014;14:42021. https:\/\/doi.org\/10.1007\/S11910-021-01152-9.","DOI":"10.1007\/S11910-021-01152-9"},{"key":"3272_CR3","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013.","journal-title":"Cell"},{"key":"3272_CR4","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1158\/1078-0432.CCR-24-0562","volume":"30","author":"AM Nasser","year":"2024","unstructured":"Nasser AM, Melamed L, Wetzel EA, Chen JC, Nagashima CH, Kitagawa Y, et al. CDKN2A\/B Homozygous Deletion Sensitizes IDH-Mutant Glioma to CDK4\/6 Inhibition. Clin Cancer Res. 2024;30:2996\u20133005. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-0562.","journal-title":"Clin Cancer Res"},{"key":"3272_CR5","doi-asserted-by":"publisher","unstructured":"Harim Koo SW, Choi et al. Hee Jin Cho, In Hee Lee, Doo Sik Kong, Ho Jun Seol,. Ethnic delineation of primary glioblastoma genome. Cancer Medicine. 2020;9:7352. https:\/\/doi.org\/10.1002\/CAM4.3370.","DOI":"10.1002\/CAM4.3370"},{"key":"3272_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s44321-026-00393-w","author":"S Lier","year":"2026","unstructured":"Lier S, Markusson SB, Kocijancic A, Narum M, Lund SO, B\u00f6llering B, et al. CDK12\/CDK13 inhibition disrupts transcriptional elongation and replication fork progression in glioblastoma. EMBO Mol Med. 2026. https:\/\/doi.org\/10.1038\/s44321-026-00393-w.","journal-title":"EMBO Mol Med"},{"key":"3272_CR7","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2020-0509","author":"L Denis","year":"2020","unstructured":"Denis L, Jardim, Sherri Z, Millis JS, Ross M, Sue-Ann Woo, Siraj M, Ali, Razelle Kurzrock. Cyclin Pathway Genomic Alterations Across 190,247 Solid Tumors: Leveraging Large-Scale Data to Inform Therapeutic Directions. Oncologist. 2020. https:\/\/doi.org\/10.1634\/theoncologist.2020-0509."},{"key":"3272_CR8","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s41420-021-00423-1","volume":"7","author":"D Christin Riess","year":"2021","unstructured":"Christin Riess D, Koczan Bj\u00f6rn, Schneider C, Linke. Katharina del Moral, Carl Friedrich Classen, Claudia Maletzki. Cyclin-dependent kinase inhibitors exert distinct effects on patient-derived 2D and 3D glioblastoma cell culture models. Cell Death Discovery. 2021;7:54. https:\/\/doi.org\/10.1038\/s41420-021-00423-1.","journal-title":"Cell Death Discovery"},{"key":"3272_CR9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/ctm2.70448","volume":"15","author":"JV Thomas Freitag","year":"2025","unstructured":"Thomas Freitag JV, Scheffler P, Kaps A, Hieltscher Bj\u00f6rn, Schneider D, Dubinski, et al. CDK7 inhibition promotes glioblastoma cell death through convergent transcriptional and metabolic stress pathways. Clin Translational Med. 2025;15:4\u201311. https:\/\/doi.org\/10.1002\/ctm2.70448.","journal-title":"Clin Translational Med"},{"key":"3272_CR10","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41419-022-05006-1","volume":"13","author":"C Riess","year":"2022","unstructured":"Riess C, Del Moral K, Fiebig A, Kaps P, Linke C, Hinz B, et al. Implementation of a combined CDK inhibition and arginine-deprivation approach to target arginine-auxotrophic glioblastoma multiforme cells. Cell Death Dis. 2022;13:555. https:\/\/doi.org\/10.1038\/s41419-022-05006-1.","journal-title":"Cell Death Dis"},{"key":"3272_CR11","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-25-0277","author":"N Sidharth","year":"2025","unstructured":"Sidharth N, Gadgil AS, Karve GA, Gudelsky, Bhavesh B, Gabani M, Medvedovic SP, Kulkarni, et al. Preclinical Evaluation of the Efficacy of a Cyclin-dependent Kinase Inhibitor Ribociclib in Combination with Letrozole Against Patient-Derived Glioblastoma Cells. Mol Cancer Ther. 2025. https:\/\/doi.org\/10.1158\/1535-7163.MCT-25-0277.","journal-title":"Mol Cancer Ther"},{"key":"3272_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0234103","author":"C Sheelagh Frame","year":"2020","unstructured":"Sheelagh Frame C, Saladino C, MacKay B, Atrash P, Sheldrake E, McDonald, et al. Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer. PLoS ONE. 2020. https:\/\/doi.org\/10.1371\/journal.pone.0234103.","journal-title":"PLoS ONE"},{"key":"3272_CR13","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1093\/HMG\/10.7.699","volume":"10","author":"JR Nevins","year":"2001","unstructured":"Nevins JR. The Rb\/E2F pathway and cancer. Hum Mol Genet. 2001;10:699\u2013703. https:\/\/doi.org\/10.1093\/HMG\/10.7.699.","journal-title":"Hum Mol Genet"},{"key":"3272_CR14","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1126\/SCIENCE.1388288","volume":"257","author":"A Koff","year":"1992","unstructured":"Koff A, Giordano A, Desai D, Yamashita K, Harper JW, Elledge S, et al. Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science. 1992;257:1689\u201394. https:\/\/doi.org\/10.1126\/SCIENCE.1388288.","journal-title":"Science"},{"key":"3272_CR15","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1002\/J.1460-2075.1992.TB05135.X","volume":"11","author":"M Pagano","year":"1992","unstructured":"Pagano M, Pepperkok R, Verde F, Ansorge W, Draetta G. Cyclin A is required at two points in the human cell cycle. EMBO J. 1992;11:961\u201371. https:\/\/doi.org\/10.1002\/J.1460-2075.1992.TB05135.X.","journal-title":"EMBO J"},{"key":"3272_CR16","doi-asserted-by":"publisher","unstructured":"Goodrich J, Taatjes D. Transcription regulation enters a new phase. Nature 2018 560:7717. 2018;558:197\u20138. https:\/\/doi.org\/10.1038\/D41586-018-05244-4.","DOI":"10.1038\/D41586-018-05244-4"},{"key":"3272_CR17","doi-asserted-by":"publisher","first-page":"5543","DOI":"10.1007\/S00018-021-03878-8","volume":"78","author":"Sylvain Egloff","year":"2021","unstructured":"Sylvain Egloff. CDK9 keeps RNA polymerase II on track. Cell Mol Life Sci. 2021;78:5543\u201367. https:\/\/doi.org\/10.1007\/S00018-021-03878-8.","journal-title":"Cell Mol Life Sci"},{"key":"3272_CR18","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1101\/GAD.269589.115","volume":"30","author":"RS Miriam Sans\u00f3","year":"2016","unstructured":"Miriam Sans\u00f3 RS, Levin JJ, Lipp VYF, Wang AK, Greifenberg EM, Quezada, et al. P-TEFb regulation of transcription termination factor Xrn2 revealed by a chemical genetic screen for Cdk9 substrates. Genes Dev. 2016;30:117\u201331. https:\/\/doi.org\/10.1101\/GAD.269589.115.","journal-title":"Genes Dev"},{"key":"3272_CR19","doi-asserted-by":"publisher","first-page":"113475","DOI":"10.1016\/j.ejca.2023.113475","volume":"198","author":"E Le Rhun","year":"2024","unstructured":"Le Rhun E, Gorlia T, Felsberg J, Jongen J, Maurage C-A, Ducray F, et al. Zotiraciclib (TG02) for newly diagnosed glioblastoma in the elderly or for recurrent glioblastoma: The EORTC 1608 STEAM trial. Eur J cancer (Oxford England: 1990). 2024;198:113475. https:\/\/doi.org\/10.1016\/j.ejca.2023.113475.","journal-title":"Eur J cancer (Oxford England: 1990)"},{"key":"3272_CR20","doi-asserted-by":"publisher","first-page":"678559","DOI":"10.3389\/FONC.2021.678559\/FULL","volume":"11","author":"AT Anshabo","year":"2021","unstructured":"Anshabo AT, Milne R, Wang S, Albrecht H. CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents. Front Oncol. 2021;11:678559. https:\/\/doi.org\/10.3389\/FONC.2021.678559\/FULL.","journal-title":"Front Oncol"},{"key":"3272_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41388-024-02982-w","volume":"17","author":"CA Luigi Alfano","year":"2024","unstructured":"Luigi Alfano CA, Iannuzzi D, Barone IM, Forte MC, Ragosta M, Cuomo, et al. CDK9-55 guides the anaphase-promoting complex\/cyclosome (APC\/C) in choosing the DNA repair pathway choice. Oncogene 1998. 2024;17:25. https:\/\/doi.org\/10.1038\/s41388-024-02982-w.","journal-title":"Oncogene 1998"},{"key":"3272_CR22","doi-asserted-by":"publisher","unstructured":"Harri M, Itkonen N, Poulose S, Walker IG, Mills. CDK9 Inhibition Induces a Metabolic Switch that Renders Prostate Cancer Cells Dependent on Fatty Acid Oxidation. Neoplasia (New York, N.Y.). 2019;21:713. https:\/\/doi.org\/10.1016\/J.NEO.2019.05.001.","DOI":"10.1016\/J.NEO.2019.05.001"},{"key":"3272_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-026-02704-8","author":"Z Huang","year":"2026","unstructured":"Huang Z, Duan X, Ji J, Cai Q, Jin P, Yu B, Zhang J. Deconstructing cancer in 3D: models, mechanisms, and personalized solutions. Mol Cancer. 2026. https:\/\/doi.org\/10.1186\/s12943-026-02704-8.","journal-title":"Mol Cancer"},{"key":"3272_CR24","doi-asserted-by":"publisher","first-page":"e22276","DOI":"10.1002\/advs.202522276","volume":"13","author":"D Patra","year":"2026","unstructured":"Patra D, Sayed IM, Mukherjee S, Piplani H, Habtezion A, Rosen MJ, Wu JC. Integrating Human Intestinal Organoids into FDA\u2019s New Approach Methodologies for Drug Discovery. Adv Sci. 2026;13:e22276. https:\/\/doi.org\/10.1002\/advs.202522276.","journal-title":"Adv Sci"},{"key":"3272_CR25","doi-asserted-by":"publisher","unstructured":"Slovackova J, Bernatik O, Cimborova K, Barak M, Hendrych M, Kocourkova K, et al. From patient to tumor organoid: Culture protocol choice controls glioblastoma tumor architecture and identity. Brain Pathol. 2026;e70125. https:\/\/doi.org\/10.1111\/bpa.70125.","DOI":"10.1111\/bpa.70125"},{"key":"3272_CR26","doi-asserted-by":"publisher","first-page":"3334","DOI":"10.3390\/ijms26073334","volume":"26","author":"S-C Nelz","year":"2025","unstructured":"Nelz S-C, L\u00fcck E, Sch\u00f6lzel A, Sauer M, Heskamp J, Doss S. Ex Vivo Plasma Application on Human Brain Microvascular Endothelial-like Cells for Blood-Brain Barrier Modeling. Int J Mol Sci. 2025;26:3334. https:\/\/doi.org\/10.3390\/ijms26073334.","journal-title":"Int J Mol Sci"},{"key":"3272_CR27","doi-asserted-by":"publisher","unstructured":"Hannes Forkel P, Grabarczyk M, Depke S, Troschke-Meurer S, Simm E, Hammer et al. BCL11B depletion induces the development of highly cytotoxic innate T cells out of IL-15 stimulated peripheral blood \u03b1\u03b2 CD8\u2009+\u2009T cells. OncoImmunology. 2022. https:\/\/doi.org\/10.1080\/2162402X.2022.2148850.","DOI":"10.1080\/2162402X.2022.2148850"},{"key":"3272_CR28","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3390\/CANCERS15030904\/S1","volume":"15","author":"ST-MM Zumpe","year":"2023","unstructured":"Zumpe ST-MM, Mei\u00dfner L, Siebert N, Grabarczyk P, Forkel H, et al. Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models. Cancers. 2023;15:904. https:\/\/doi.org\/10.3390\/CANCERS15030904\/S1.","journal-title":"Cancers"},{"issue":"1","key":"3272_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41420-023-01671-z","volume":"9","author":"C Maletzki","year":"2023","unstructured":"Maletzki C, Grote VF, Kalle F, Kleitke T, Zimpfer A, Becker AS, et al. Establishing safe high hydrostatic pressure devitalization thresholds for autologous head and neck cancer vaccination and reconstruction. Cell Death Discovery 2023. 2023;9(1):9:1\u201311. https:\/\/doi.org\/10.1038\/s41420-023-01671-z.","journal-title":"Cell Death Discovery 2023"},{"key":"3272_CR30","doi-asserted-by":"publisher","unstructured":"Thomas Freitag P, Kaps J, Ramtke S, Bertels E, Zunke, Bj\u00f6rn, Schneider et al. Combined inhibition of EZH2 and CDK4\/6 perturbs endoplasmic reticulum-mitochondrial homeostasis and increases antitumor activity against glioblastoma. NPJ precision oncology. 2024. https:\/\/doi.org\/10.1038\/S41698-024-00653-3.","DOI":"10.1038\/S41698-024-00653-3"},{"key":"3272_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05006-1","author":"Kdel Christin Riess","year":"2022","unstructured":"Christin Riess Kdel, Moral A, Fiebig P, Kaps C, Linke B, Hinz, et al. Implementation of a combined CDK inhibition and arginine-deprivation approach to target arginine-auxotrophic glioblastoma multiforme cells. Cell Death Dis. 2022. https:\/\/doi.org\/10.1038\/s41419-022-05006-1.","journal-title":"Cell Death Dis"},{"key":"3272_CR32","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1016\/j.vaccine.2012.01.071","volume":"30","author":"U Klier","year":"2012","unstructured":"Klier U, Maletzki C, Kreikemeyer B, Klar E, Linnebacher M. Combining bacterial-immunotherapy with therapeutic antibodies: A novel therapeutic concept. Vaccine. 2012;30:2786\u201394. https:\/\/doi.org\/10.1016\/j.vaccine.2012.01.071.","journal-title":"Vaccine"},{"key":"3272_CR33","doi-asserted-by":"publisher","first-page":"9534","DOI":"10.1038\/s41598-026-42867-4","volume":"16","author":"A Wolff","year":"2026","unstructured":"Wolff A, Waitz G, Kaps P, Oehmcke-Hecht S, Bergmann-Ewert W, Schneider B, et al. Exploring the dual role of extracellular vesicles in coagulation and immune modulation in glioblastoma. Sci Rep. 2026;16:9534. https:\/\/doi.org\/10.1038\/s41598-026-42867-4.","journal-title":"Sci Rep"},{"key":"3272_CR34","doi-asserted-by":"publisher","unstructured":"Maletzki C, Freitag T, Hempelmann A, Wolff A, Freiman TM, Won S-Y, et al. Tumor treating fields alter local coagulation dynamics in glioblastoma patients. Neurotherapeutics. 2025;e00715. https:\/\/doi.org\/10.1016\/j.neurot.2025.e00715.","DOI":"10.1016\/j.neurot.2025.e00715"},{"key":"3272_CR35","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/nprot.2008.211","volume":"15","author":"DW Huang","year":"2008","unstructured":"Huang DW, Brad T, Sherman RA, Lempicki. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protocols 2020. 2008;15:10. https:\/\/doi.org\/10.1038\/nprot.2008.211.","journal-title":"Nat Protocols 2020"},{"key":"3272_CR36","doi-asserted-by":"publisher","first-page":"W216","DOI":"10.1093\/NAR\/GKAC194","volume":"50","author":"T Brad","year":"2022","unstructured":"Brad T, Sherman M, Hao J, Qiu X, Baseler JMW, Clifford H, Lane, et al. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 2022;50:W216. https:\/\/doi.org\/10.1093\/NAR\/GKAC194.","journal-title":"Nucleic Acids Res"},{"key":"3272_CR37","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1158\/1535-7163.MCT-19-0987","volume":"20","author":"M Kawakami","year":"2021","unstructured":"Kawakami M, Mustachio LM, Chen Y, Chen Z, Liu X, Wei C-H, et al. A Novel CDK2\/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers. Mol Cancer Ther. 2021;20:477\u201389. https:\/\/doi.org\/10.1158\/1535-7163.MCT-19-0987.","journal-title":"Mol Cancer Ther"},{"key":"3272_CR38","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41593-020-00789-y","volume":"24","author":"ARP Antunes","year":"2021","unstructured":"Antunes ARP, Scheyltjens I, Lodi F, Messiaen J, Antoranz A, Duerinck J, et al. Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization. Nat Neurosci 2021. 2021;24:4. https:\/\/doi.org\/10.1038\/s41593-020-00789-y.","journal-title":"Nat Neurosci 2021"},{"key":"3272_CR39","doi-asserted-by":"publisher","first-page":"2279241","DOI":"10.1080\/15384047.2023.2279241","volume":"24","author":"Z Chen","year":"2023","unstructured":"Chen Z, Liu X, Kawakami M, Liu X, Baker A, Bhatawadekar A, et al. CDK2 inhibition disorders centrosome stoichiometry and alters cellular outcomes in aneuploid cancer cells. Cancer Biology Therapy. 2023;24:2279241. https:\/\/doi.org\/10.1080\/15384047.2023.2279241.","journal-title":"Cancer Biology Therapy"},{"key":"3272_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-021-04050-7","volume":"12","author":"L Viktorija Juric","year":"2021","unstructured":"Viktorija Juric L, Hudson J, Fay CE, Richards H, Jahns Ma\u00eft\u00e9, Verreault, et al. Transcriptional CDK inhibitors, CYC065 and THZ1 promote Bim-dependent apoptosis in primary and recurrent GBM through cell cycle arrest and Mcl-1 downregulation. Cell Death Dis. 2021;12:1\u201312. https:\/\/doi.org\/10.1038\/s41419-021-04050-7.","journal-title":"Cell Death Dis"},{"key":"3272_CR41","doi-asserted-by":"publisher","first-page":"6983","DOI":"10.7150\/THNO.111972","volume":"15","author":"X Nan Wen","year":"2025","unstructured":"Nan Wen X, Xiao H, Lu Q, Chen G, He Z, Qian, et al. Immuno-oncological interactions between meningeal lymphatics and glioblastoma: from mechanisms to therapies. Theranostics. 2025;15:6983\u20137000. https:\/\/doi.org\/10.7150\/THNO.111972.","journal-title":"Theranostics"},{"key":"3272_CR42","doi-asserted-by":"publisher","unstructured":"Shapiro G, Patnaik A, Lee S, Rosen SM, Tolaney AW, Tolcher JW, Goldman et al. Effi cacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-0095.","DOI":"10.1158\/2159-8290.CD-16-0095"},{"key":"3272_CR43","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/S11523-020-00789-9","volume":"16","author":"J Zhang","year":"2021","unstructured":"Zhang J, Yang N, Ji D, Shen W, Li W, Han R, et al. A Randomized Phase I Study of Abemaciclib in Chinese Patients with Advanced and\/or Metastatic Cancers. Target Oncol. 2021;16:177. https:\/\/doi.org\/10.1007\/S11523-020-00789-9.","journal-title":"Target Oncol"},{"key":"3272_CR44","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1074\/JBC.M406293200","volume":"280","author":"B Shan","year":"2005","unstructured":"Shan B, Zhuo Y, Chin D, Morris CA, Gilbert F, Morris JA. Lasky. Cyclin-dependent Kinase 9 Is Required for Tumor Necrosis Factor-\u03b1-stimulated Matrix Metalloproteinase-9 Expression in Human Lung Adenocarcinoma Cells. J Biol Chem. 2005;280:1103\u201311. https:\/\/doi.org\/10.1074\/JBC.M406293200.","journal-title":"J Biol Chem"},{"key":"3272_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-024-66105-x","volume":"14","author":"Y Zijun Wu","year":"2024","unstructured":"Zijun Wu Y, Yang M, Chen Y, Zha. Matrix metalloproteinase 9 expression and glioblastoma survival prediction using machine learning on digital pathological images. Sci Rep. 2024;14:1\u201311. https:\/\/doi.org\/10.1038\/s41598-024-66105-x.","journal-title":"Sci Rep"},{"key":"3272_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0312764","author":"Y Han Cheng","year":"2025","unstructured":"Han Cheng Y, Yan B, Zhang Z, Ma S, Fu Z, Ji, et al. Single-cell transcriptomics reveals immunosuppressive microenvironment and highlights tumor-promoting macrophage cells in Glioblastoma. PLoS ONE. 2025. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0312764.","journal-title":"PLoS ONE"},{"key":"3272_CR47","doi-asserted-by":"publisher","first-page":"5875","DOI":"10.1172\/JCI134132","volume":"130","author":"E Poon","year":"2020","unstructured":"Poon E, Liang T, Jamin Y, Walz S, Kwok C, Hakkert A, et al. Orally bioavailable CDK9\/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma. J Clin Investig. 2020;130:5875\u201392. https:\/\/doi.org\/10.1172\/JCI134132.","journal-title":"J Clin Investig"},{"key":"3272_CR48","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1136\/gutjnl-2019-320441","volume":"70","author":"P Jin Huang","year":"2021","unstructured":"Jin Huang P, Chen K, Liu J, Liu B, Zhou R, Wu, et al. CDK1\/2\/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer. Gut. 2021;70:890\u20139. https:\/\/doi.org\/10.1136\/gutjnl-2019-320441.","journal-title":"Gut"},{"key":"3272_CR49","doi-asserted-by":"publisher","unstructured":"Liu J, Kang R, Tang D. CDK1\/2\/5 blockade: killing two birds with one stone. 2021. https:\/\/doi.org\/10.1080\/2162402X.2017.1343775. doi:10.1080\/2162402X.2021.1875612 .","DOI":"10.1080\/2162402X.2017.1343775"},{"key":"3272_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/S12943-025-02339-1","author":"L Gustavo Baldassarre, Ivana","year":"2025","unstructured":"Gustavo Baldassarre, Ivana L, de la Serna Fran\u00e7oisM, Vallette. Death-ision: the link between cellular resilience and cancer resistance to treatments. Mol Cancer. 2025. https:\/\/doi.org\/10.1186\/S12943-025-02339-1.","journal-title":"Mol Cancer"},{"key":"3272_CR51","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.4049\/jimmunol.162.4.2326","volume":"162","author":"P Saas","year":"1999","unstructured":"Saas P, Boucraut J, Quiquerez A-L, Schnuriger V, Perrin G, Desplat-Jego S, et al. CD95 (Fas\/Apo-1) as a Receptor Governing Astrocyte Apoptotic or Inflammatory Responses: A Key Role in Brain Inflammation?1. J Immunol. 1999;162:2326\u201333. https:\/\/doi.org\/10.4049\/jimmunol.162.4.2326.","journal-title":"J Immunol"},{"key":"3272_CR52","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/J.OMTN.2019.09.005","volume":"18","author":"Y Keman Liao","year":"2019","unstructured":"Keman Liao Y, Lin W, Gao Z, Xiao R, Medina P, Dmitriev, et al. Blocking lncRNA MALAT1\/miR-199a\/ZHX1 Axis Inhibits Glioblastoma Proliferation and Progression. Mol Therapy - Nucleic Acids. 2019;18:388\u201399. https:\/\/doi.org\/10.1016\/J.OMTN.2019.09.005.","journal-title":"Mol Therapy - Nucleic Acids"},{"key":"3272_CR53","doi-asserted-by":"publisher","first-page":"144518","DOI":"10.1016\/J.GENE.2020.144518","volume":"739","author":"I Yucel Baspinar","year":"2020","unstructured":"Yucel Baspinar I, Elmaci A, Ozpinar MA, Altinoz. Long non-coding RNA MALAT1 as a key target in pathogenesis of glioblastoma. Janus faces or Achilles\u2019 heal? Gene. 2020;739:144518. https:\/\/doi.org\/10.1016\/J.GENE.2020.144518.","journal-title":"Janus faces or Achilles\u2019 heal? Gene"},{"key":"3272_CR54","doi-asserted-by":"publisher","first-page":"120611","DOI":"10.1016\/J.BIOMATERIALS.2020.120611","volume":"269","author":"Fr\u00e9d\u00e9ric Marie Cuvellier","year":"2021","unstructured":"Marie Cuvellier Fr\u00e9d\u00e9ric, Ezan H, Oliveira S, Rose JC, Fricain S, Langou\u00ebt, et al. 3D culture of HepaRG cells in GelMa and its application to bioprinting of a multicellular hepatic model. Biomaterials. 2021;269:120611. https:\/\/doi.org\/10.1016\/J.BIOMATERIALS.2020.120611.","journal-title":"Biomaterials"},{"key":"3272_CR55","doi-asserted-by":"publisher","first-page":"990","DOI":"10.3892\/OL.2018.9687","volume":"17","author":"X Hou","year":"2018","unstructured":"Hou X, Niu Z, Liu L, Guo Q, Li H, Yang X, Zhang X. miR-1207-5p regulates the sensitivity of triple-negative breast cancer cells to Taxol treatment via the suppression of LZTS1 expression. Oncol Lett. 2018;17:990. https:\/\/doi.org\/10.3892\/OL.2018.9687.","journal-title":"Oncol Lett"},{"key":"3272_CR56","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/S41419-021-03461-W","volume":"12","author":"C Zhang","year":"2021","unstructured":"Zhang C, Wang L, Jin C, Zhou J, Peng C, Wang Y, et al. Long non-coding RNA Lnc-LALC facilitates colorectal cancer liver metastasis via epigenetically silencing LZTS1. Cell Death Dis. 2021;12:224. https:\/\/doi.org\/10.1038\/S41419-021-03461-W.","journal-title":"Cell Death Dis"},{"key":"3272_CR57","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/J.BIOPHA.2015.10.006","volume":"76","author":"Y He","year":"2015","unstructured":"He Y, Liu X. The tumor-suppressor gene LZTS1 suppresses hepatocellular carcinoma proliferation by impairing PI3K\/Akt pathway. Biomed Pharmacother. 2015;76:141\u20136. https:\/\/doi.org\/10.1016\/J.BIOPHA.2015.10.006.","journal-title":"Biomed Pharmacother"},{"key":"3272_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/S12935-020-01530-2","author":"J Tian","year":"2020","unstructured":"Tian J, Cui P, Li Y, Yao X, Wu X, Wang Z, Li C. LINC02418 promotes colon cancer progression by suppressing apoptosis via interaction with miR-34b-5p\/BCL2 axis. Cancer Cell Int. 2020. https:\/\/doi.org\/10.1186\/S12935-020-01530-2.","journal-title":"Cancer Cell Int"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-026-03272-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-03272-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-03272-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T06:31:36Z","timestamp":1791009096000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12964-026-03272-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3272"],"URL":"https:\/\/doi.org\/10.1186\/s12964-026-03272-6","relation":{"references":[{"id-type":"doi","id":"10.1634\/theoncologist.2020-0509","asserted-by":"subject"}]},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"assertion":[{"value":"9 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All cell lines used in this study were originally established from tumor tissue with informed written patient consent. All procedures were approved by the Ethics Committee of the Rostock University Medical Center, University of Rostock (Ethikkommission an der Medizinischen Fakult\u00e4t der Universit\u00e4t Rostock, St.-Georg-Str. 108, 18055 Rostock, Germany; Ethics Registration ID: A2018-0167) in accordance with generally accepted guidelines and the Declaration of Helsinki for the use of human material.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"529"}}